Hims & Hers Stock Plummets as Novo Nordisk Ends Wegovy Deal Over Marketing Concerns
Originally Published 6 months ago — by TipRanks

Hims & Hers stock dropped about 35% after Novo Nordisk ended its partnership, citing illegal sales of copycat drugs, leading to multiple analyst downgrades due to legal and competitive concerns. Wall Street remains cautious, with a consensus of hold ratings and concerns over potential litigation and impact on revenue.
